CancerWorld shared a post on LinkedIn:
“Every scientific revolution begins with someone unwilling to stop asking one question: Why?
As a child, Brian Druker took apart clocks to understand how they worked. Decades later, the same curiosity led him to challenge how cancer itself could be treated—helping pave the way for imatinib and the era of targeted therapy.
Twenty-five years after one of oncology’s defining breakthroughs, Dr. Druker reflects on the curiosity, setbacks, and patients who shaped a discovery that transformed the lives of people with chronic myeloid leukaemia.
It’s a reminder that behind every breakthrough is not only great science, but the people courageous enough to question what everyone else accepts.
Read the full interview by Aleksandra Filipovic.”
Other posts about CancerWorld on OncoDaily.